**Figure 7.** **Identification of upstream potential pseudogenes of hsa-miR-363-3p in ovarian cancer.** (**A**) The pseudogenes-hsa-miR-363-3p network constructed by Cytoscape. The expression levels of RPS26P15 (**B**), AC004057.1 (**C**), RPS26P31 (**D**), RPS26P6 (**E**), RPS26P3 (**F**) and RPS26P47 (**G**) in ovarian cancer compared with normal controls. “*” represents “P-value < 0.05”. Y axis indicates relative expression value, log_{2}(TPM+1). TPM=Transcript per million. Expression differences of RPS26P15 (**H**), AC004057.1 (**I**), RPS26P31 (**J**), RPS26P6 (**K**), RPS26P3 (**L**) and RPS26P47 (**M**) among various major stage in ovarian cancer. P-value < 0.05 was considered as statistically significant. (**N**) The expression correlation of hsa-miR-363-3p and RPS26P15 in ovarian cancer. (**O**) The expression correlation of hsa-miR-363-3p and AC004057.1 in ovarian cancer. (**P**) The expression correlation of hsa-miR-363-3p and RPS26P31 in ovarian cancer. (**Q**) The expression correlation of hsa-miR-363-3p and RPS26P6 in ovarian cancer. (**R**) The expression correlation of hsa-miR-363-3p and RPS26P3 in ovarian cancer. (**S**) The expression correlation of hsa-miR-363-3p and RPS26P47 in ovarian cancer.